163 related articles for article (PubMed ID: 26968814)
1. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M; Fleitas T; Llorca-Cardeñosa MJ; Mongort C; Alonso E; Navarro S; Burgues O; Vivancos A; Cejalvo JM; Perez-Fidalgo JA; Roselló S; Ribas G; Cervantes A
Oncotarget; 2016 Apr; 7(16):22543-55. PubMed ID: 26968814
[TBL] [Abstract][Full Text] [Related]
2. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.
Fleitas T; Ibarrola-Villava M; Ribas G; Cervantes A
Cancer Treat Rev; 2016 Sep; 49():57-64. PubMed ID: 27501018
[TBL] [Abstract][Full Text] [Related]
3. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D; Gavin PG; Taniyama Y; Kim SI; Choi HJ; Paik S; Pogue-Geile KL
BMC Cancer; 2010 Mar; 10():101. PubMed ID: 20233444
[TBL] [Abstract][Full Text] [Related]
4. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G; Grassini G; Bartocci P; Francaviglia I; Dal Cin E; Barbieri G; Arrigoni G; Pecciarini L; Doglioni C; Cangi MG
Oncotarget; 2015 Oct; 6(31):30592-603. PubMed ID: 26435479
[TBL] [Abstract][Full Text] [Related]
5. Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy.
Fleitas-Kanonnikoff T; Martinez-Ciarpaglini C; Ayala J; Gauna C; Denis R; Yoffe I; Sforza S; Martínez MT; Pomata A; Ibarrola-Villava M; Arevshatyan S; Burriel V; Boscá D; Pastor O; Ferrer-Martinez A; Carrasco F; Mongort C; Navarro S; Ribas G; Cervantes A
Cancer Med; 2019 Jun; 8(6):3120-3130. PubMed ID: 31059199
[TBL] [Abstract][Full Text] [Related]
6. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Muller E; Brault B; Holmes A; Legros A; Jeannot E; Campitelli M; Rousselin A; Goardon N; Frébourg T; Krieger S; Crouet H; Nicolas A; Sastre X; Vaur D; Castéra L
Cancer Med; 2015 Oct; 4(10):1484-93. PubMed ID: 26155992
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
8. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM
J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902
[TBL] [Abstract][Full Text] [Related]
10. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
11. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
12. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract][Full Text] [Related]
14. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
15. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
16. Somatic DNA Mutation Analysis.
O'Grady A; Cummins R
Methods Mol Biol; 2017; 1606():219-233. PubMed ID: 28502004
[TBL] [Abstract][Full Text] [Related]
17. Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.
Sherwood JL; Müller S; Orr MC; Ratcliffe MJ; Walker J
PLoS One; 2014; 9(6):e100566. PubMed ID: 24956168
[TBL] [Abstract][Full Text] [Related]
18. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
20. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
